Discover How Arima Technology Unlocks New Insights for Disease Research
Structural variants have broad impacts on human health and disease. These variants include translocations, inversions, deletions and duplications that are associated with genetic disorders such as cancer. In fact, 95% of characterized tumor samples analyzed by the International Cancer Genome Consortium contain one or more structural variants.
Arima Genomics is announcing early access to our new:
Arima-HiC+ FFPE kit to expand the utility of formalin fixed paraffin embedded tissues — a critical sample type for disease researchers — for use in the Arima-HiC+ workflow
Arima-SV pipeline, which enables researchers to discover translocations, duplications, inversions and deletions in any sample type using short-read sequencing approaches including Illumina sequencing.
Specifically, this technology will allow scientists to:
Detect coding and non-coding structural variants using Hi-C data and our optimized bioinformatics pipeline
Link structural variants to impacts on gene function by mapping 3D interactions between the variant and the affected gene
Expand the detection and discovery of structural variants by enabling characterization of archival FFPE tissue samples
Detect Coding and Non-Coding Structural Variants
Arima Hi-C technology retains the 3D properties of the genome to characterize chromosomal organization. Using this same technology and our new Arima Structural Variant bioinformatics pipeline, researchers can concurrently detect structural rearrangements in the genome.
Link Structural Variants to Impacts on Gene Function
To understand the role of structural variants in tumorigenesis it is critical to know how they impact gene regulation. With Arima Hi-C technologies, you can capture the location of structural variants, gene activity with H32K27ac, and the resulting 3D interactions caused by the structural variants to determine the impacts on gene regulation.
Discover How 3D Genomics is Enabling Structural Variant Detection
Hear from Anthony Schmitt, SVP of Science, about the launch of the Arima-HiC+ FFPE kit and Arima-SV pipeline.
Expand the Detection and Discovery of Structural Variants
Access to patient samples is critical to expanding our understanding of disease and the mechanisms that drive it. However, the widely collected sample type of FFPE tissues performs poorly in most molecular assays. To unlock the potential of these samples, Arima Genomics has developed the Arima-HiC+ FFPE sample preparation kit that allows researchers to obtain Hi-C data and detect structural variants using this critical sample type.